Diagnostic and Interventional Cardiology

MedWatch, The FDA Safety Information and Adverse Event Reporting Program, announced that Pfizer is recalling Accuretic (quinapril hydrochloride/hydrochlorothiazide) tablets distributed by Pfizer as well as two authorized generics distributed by Greenstone (quinapril HCL and hydrochlorothiazide and quinapril HCl/hydrochlorothiazide) due to the presence of a nitrosamine, N-nitroso-quinapril, above the Acceptable Daily Intake level.

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Top 10: Most Read Cardiology Content in March 2022

Here is what you and your colleagues found to be most interesting in the field of cardiology during the month of March ...

March 31, 2022

The annual congress of the European Heart Rhythm Association (EHRA), a branch of the ESC, will be held April 3-5 at the Bella Center in Copenhagen, Denmark and online. Explore the scientific program.

News | ESC

EHRA 2022: Cutting Edge Science in Heart Rhythm Disorders

March 31, 2022 — The annual congress of the European Heart Rhythm Association (EHRA), a branch of the ESC, will be held ...

March 31, 2022

Investigators from Cedars-Sinai have created an artificial intelligence-enabled tool that may make it easier to predict if a person will have a heart attack.

News | CT Angiography (CTA)

Artificial Intelligence Tool May Help Predict Heart Attacks

March 31, 2022 – Investigators from Cedars-Sinai have created an artificial intelligence-enabled tool that may make it ...

March 31, 2022

Sponsored Content

Patient applying a Cardiac Insight Cardea SOLO monitoring device at home. The remote, physician-prescribed and patient self-applied device is worn for a specified period of monitoring time and then returned to the physician office for report creation.

Feature | Atrial Fibrillation

Increasing Early Detection of Atrial Fibrillation Through Improved Short-Term Monitoring

Improved short-term monitoring methods for patients with stroke risk can increase early detection of atrial fibrillation ...

December 07, 2021

DiA Imaging Analysis Ltd, a leading global provider of AI-powered ultrasound analysis software, announced today a multi-year agreement with Change Healthcare, a global industry-leading provider of enterprise imaging solutions.

News | Cardiovascular Ultrasound

DiA Imaging Analysis Teams up with Healthcare Technology Company to Expand its AI Offering for Echo-lab Cardiac Exams

March 31, 2022 – DiA Imaging Analysis Ltd, a leading global provider of AI-powered ultrasound analysis software ...

March 31, 2022

Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has successfully completed enrollment in its phase 2 study of istaroxime in early cardiogenic shock caused by heart failure.

News | Pharmaceuticals

Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock

March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions ...

March 31, 2022

Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the publication of results from the first-in-human clinical trial of Embrace Hydrogel Embolic System (HES) for the treatment of hypervascular tumors, in the Journal of Vascular and Interventional Radiology (JVIR).

News | Embolization devices

Instylla First-In-Human Clinical Trial Published Results Demonstrate Technical Success and Persistent Embolization Across All Patients

March 31, 2022 – Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral ...

March 31, 2022

Sponsored Content

Cardiovascular Ultrasound Analytics Aids Re-accreditation Process

Feature | Analytics Software

The Benefits of Data Analytics in Clinical Reporting

Accurate reporting is essential to producing the reliable analytics needed to meet lab accreditation standards. This is ...

October 27, 2021

Vivasure Medical, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the first patient was treated in a U.S. early feasibility study evaluating PerQseal+, the next generation of the company’s PerQseal device.

News | Structural Heart

Vivasure Medical Announces First Patient Treated in U.S. Early Feasibility Study Evaluating PerQseal+

March 31, 2022 – Vivasure Medical, a company pioneering novel fully absorbable technology for percutaneous vessel ...

March 31, 2022

One in 5 people worldwide have high Lipoprotein(a) – sometimes referred to as “L-P-little a” – an important genetic risk factor for premature heart disease and stroke.

News | Heart Failure

The Silent, Undetected Cause of Early Heart Disease

March 31, 2022 – One in 5 people worldwide have high Lipoprotein(a) – sometimes referred to as “L-P-little a” – an ...

March 31, 2022

University Hospitals Cleveland Medical Center

News | Population Health

Study Shows Link Between Socioeconomic Deprivation and Premature Cardiovascular Mortality

March 31, 2022 – People living in socially-deprived areas of the United States are more likely to die prematurely from ...

March 31, 2022

Sponsored Content

Feature | Cardiovascular Information Systems (CVIS)

Improving Consistency and Standardization With Structured Reporting

Jeff Rieder M.D., a cardiologist with Coastal Cardiology Charleston, clearly recalls the time when reporting was ...

July 26, 2021

A study conducted at São Paulo State University (UNESP) in Brazil shows that even mild to moderate infection by SARS-CoV-2 can cause an imbalance in the cardiovascular system of young adults without pre-existing diseases.

News | Coronavirus (COVID-19)

Study: Even Mild or Moderate COVID-19 Can Affect the Cardiovascular System in Young Adults

March 31, 2022 – A study conducted at São Paulo State University (UNESP) in Brazil shows that even mild to moderate ...

March 31, 2022

Clinician-scientists in the Smidt Heart Institute at Cedars-Sinai developed a clinical algorithm that, for the first time, distinguishes between treatable sudden cardiac arrest and untreatable forms of the condition.

News | Sudden Cardiac Arrest

Cedars-Sinai Researchers Are the First to Distinguish Between Treatable and Untreatable Sudden Cardiac Arrest

March 30, 2022 — Clinician-scientists in the Smidt Heart Institute at Cedars-Sinai developed a clinical algorithm that ...

March 30, 2022

Today the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) approved the use of a second COVID-19 booster shot for adults over age 50 and certain immunocompromised individuals, including heart transplant patients.

News | Coronavirus (COVID-19)

Second Booster Approved as Option for Additional Protection Against COVID-19

March 29, 2022 — Today the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention ...

March 29, 2022

Sponsored Content

Case Study | Cardiovascular Information Systems (CVIS)

Mining Cardiology Data to Optimize Patient Care and Improve Productivity

During the COVID-19 pandemic, many cardiology departments were faced with the daunting task of supporting inpatient and ...

June 18, 2021

Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, has received US Food and Drug Administration (FDA) clearance for its Solus Gold Embolization Device, a next-generation product for peripheral vascular occlusion.

News | Embolization devices

Artio Medical Receives FDA Clearance for Solus Gold Embolization Device

March 29, 2022 – Artio Medical, Inc., a medical device company developing innovative products for the peripheral ...

March 29, 2022

News | Computed Tomography (CT)

CCT Offers a Safer Alternative to Cardiac Catheterization in CAD Diagnosis

March 29, 2022 – Cardiac computed tomography (CCT) is an accurate, noninvasive diagnostic test for obstructive coronary ...

March 29, 2022

Impulse Dynamics, a company dedicated to innovative treatments for chronic heart failure, has successfully completed the requirements for certification of its quality management system (QMS) under the new Medical Device Regulation (MDR) (EU 2017/745 ) now in force in the European Union (EU).

News | Heart Failure

Impulse Dynamics' Quality Management System Receives Certification Under European Union Medical Device Regulation

March 29, 2022 – Impulse Dynamics, a company dedicated to innovative treatments for chronic heart failure, has ...

March 29, 2022